Loading clinical trials...
Loading clinical trials...
Effect of Omega-3 Fatty Acid, Eicosapentaenoic Acid, and Its Metabolites in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase
Conditions
Interventions
Eicosapentaenoic Acid
Tyrosine kinase inhibitor
Locations
1
United States
Penn State Cancer Institute
Hershey, Pennsylvania, United States
Start Date
September 14, 2020
Primary Completion Date
May 21, 2021
Completion Date
May 21, 2021
Last Updated
July 1, 2022
NCT05143840
NCT06119269
NCT03459534
NCT03722420
NCT06233890
NCT04126681
Lead Sponsor
Milton S. Hershey Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions